Santhosh A. Upadhyaya, MD
Among pediatric patients with ependymoma, investigators found no difference in 4-year survival by molecular subgroups, according to results from the SJYC07 trial presented at the 2018 ASCO Annual Meeting.
Among patients in the posterior fossa A (PF-A) subgroup, progression-free survival (PFS) was 73.7% ± 8.5% compared with 80% ± 20.7% in the supratentorial C11 or f95RELA
-fused subgroup and 100% in the supratentorial YAP1-fused subgroup. Investigators concluded the differences were not significant (P
... to read the full story